|
|
Article: Ligand Sells More Products: $205M For Cancer Portfolio.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Ligand Pharmaceuticals Inc. has followed its sale of Avinza rights for $265 million to King Pharmaceuticals Inc. by offloading three more drugs - the rest of the firm's commercial operations - to Eisai Co. Ltd. for $205 million plus royalties, in what Ligand called an ongoing "shareholder value maximization process."
The troubled firm's accounting practices became the subject of an SEC investigation last year, and CEO David Robinson resigned at the end of July, under fire from shareholders. Ligand posted a third-quarter loss this year of $11 million, almost twice the loss during the same period in 2005 ($6.5 million), despite a 6 ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|